X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Gardasil 4 (4-valent HPV vaccine) is a vaccine indicated in girls and women 9 through 26 years of age for the prevention of Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16 and 18.
Lead Product(s): 4-valent HPV vaccine
Therapeutic Area: Oncology Product Name: Gardasil 4
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 13, 2022
Details:
Sinovac is committed to supply Bio Farma bulk vaccine to enable the latter to produce at least 40 million doses of CoronaVac in Indonesia before March 2021; after March 2021, Sinovac will continue to supply the required quantity of the bulk vaccine until the end of 2021.
Lead Product(s): CoronaVac
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac
Highest Development Status: Phase IIIProduct Type: Vaccine
Recipient: Sinovac Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 25, 2020
Details:
In the clinical trial of the 3 Covid-19 vaccines, Bio Farma will work together with the Phase 3 Clinical Trial Research Team, Faculty of Medicine, UNPAD Bandung for the next six months. If the Phase 3 clinical trial goes well, then the next step is to register with the POM.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Sinovac Biotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
